Cancer Cause and Prevention Research

Active

Assistance listing
93.393
Agency
Grant awards
18,704 $20,360,631,536 in federal obligations

Program facts

Assistance types
  • Project Grant
  • Cooperative Agreement
  • Block Grant
Treasury account
  • 75-0849-0-1-550
More information

Program details come from SAM.gov Assistance Listings. Updated . Grant award figures come from USAspending.gov.

About this program

The National Institutes of Health National Cancer Institute funds cancer cause and prevention research through CFDA 93.393, with the most recent grant award dated September 3, 2026. This program identifies cancer risks and risk reduction strategies, supports discovery of cancer etiology and prevention mechanisms, and funds both traditional research grants and SBIR/STTR commercialization initiatives across eleven research domains including chemical carcinogenesis, screening and early detection, epidemiology, nutrition, immunology and vaccines, cancer chemoprevention, clinical trials, and quality of life outcomes. Research performed must occur in the U.S. and its possessions.

Over 18,700 grants totaling $20.36 billion in federal dollars obligated since 1976 demonstrate sustained program activity. In the past five years, annual award volume has ranged from 182 to 351 awards, with 208 awards in 2026 year-to-date. The program is dominated by the National Cancer Institute, which accounts for 4,041 awards ($12.51 billion), followed by the broader NIH ($14,215 awards; $7.07 billion) and HHS ($430 awards; $738.9 million). The award portfolio is predominantly Project Grants (86%), with smaller shares of Cooperative Agreements (10%) and Block Grants (4%). Recipients include universities, colleges, hospitals, nonprofits, and for-profit organizations; SBIR applicants must be domestic small businesses with no more than 500 employees and cannot be dominant in their field.

Representative recent awards reflect the breadth of funded activities. An R01 grant to study e-cigarette influencer marketing on social media and adolescent perceptions ($733,023) addresses cancer risk reduction. A Cooperative Agreement supporting the Non-Invasive Post-Polypectomy Surveillance Study ($671,426) develops and evaluates non-invasive strategies for colorectal cancer surveillance. An R01 grant investigating the role of epigenetic factors in leukemia therapeutics ($622,070) funds basic mechanistic research. Additional recent awards support digital health interventions for symptom management after CAR-T therapy ($201,112), pharmacist-led tobacco treatment in federally qualified health centers ($669,910), and novel sunscreen formulations with DNA repair capability ($400,000).

Several opportunities remain open or recently posted. PAR-28-037, the Parent R35 Investigator-Focused Award (posted July 30, 2026), supports research programs for investigators at all career stages with funding stability and scientific freedom. RFA-CA-28-003, Advanced Development and Sustainment of Informatics Technologies for Cancer Research and Management (posted July 28, 2026), solicits U24 Cooperative Agreements to advance informatics tools and software. PAR-28-014, Early-Onset Cancers: Investigating Etiology, Mechanisms, and Early Detection Strategies (posted March 10, 2026; due October 11, 2029), invites RP1 applications investigating sporadic non-hereditary early-onset cancers in persons aged 18 to 49. PAR-28-056 and PAR-28-057, the Pancreatic Cancer Detection Consortium Research Units and Management/Data Coordination Unit (posted February 11, 2026), support multi-disciplinary teams developing and validating biomarkers for early detection and risk stratification in pancreatic ductal adenocarcinoma.

Objective and description

Objective

To identify cancer risks and risk reduction strategies, to identify factors that cause cancer in humans, and to discover and develop mechanisms for cancer prevention and preventive interventions in humans. Research programs include: (1) chemical, phy

Description

To identify cancer risks and risk reduction strategies, to identify factors that cause cancer in humans, and to discover and develop mechanisms for cancer prevention and preventive interventions in humans. Research programs include: (1) chemical, physical and molecular carcinogenesis; (2) screening, early detection and risk assessment, including biomarker discovery, development and validation; (3) epidemiology; (4) nutrition and bioactive food components; (5) immunology and vaccines; (6) field studies and statistics; (7) cancer chemoprevention and interception; (8) pre-clinical and clinical agent development; (9) organ site studies and clinical trials; (10) health-related quality of life and patient-centered outcomes; and (11) supportive care and management of symptoms and toxicities. Small Business Innovation Research (SBIR) program: To expand and improve the SBIR program; to stimulate technical innovation; to increase private sector commercialization of innovations derived from Federal research and development funding; to increase small business participation in Federal research and development; and to foster and encourage participation in innovation and entrepreneurship by women and socially/economically disadvantaged persons. Small Business Technology Transfer (STTR) program: To stimulate and foster scientific and technological innovation through cooperative research and development carried out between small business concerns and research institutions; to foster technology transfer through cooperative research and development between small business concerns and research institutions; to increase private sector commercialization of innovations derived from Federal research and development funding, and foster participation in innovation and entrepreneurship by women and socially/economically disadvantaged persons.

Eligibility

Applicant eligibility

The awardee will be a university, college, hospital, public agency, nonprofit research institution or for-profit organization that submits an application and receives a grant or cooperative agreement for support of research by a named principal investigator. SBIR grants can be awarded only to domestic small businesses (entities that are independently owned and operated for profit, are not dominant in the field in which research is proposed, and have no more than 500 employees). Primary employment (more than one- half time) of the principal investigator must be with the small business at the time of award and during the conduct of the proposed project. In both Phase I and Phase II, the research must be performed in the U.S. and its possessions. To be eligible for funding, a grant application must be approved for scientific merit and program relevance by a scientific review group and a national advisory council. STTR grants can be awarded only to domestic small business concern (entities that are independently owned and operated for profit, are not dominant in the field in which research is proposed and have no more than 500 employees) which "partner" with a research institution in cooperative research and development. At least 40 percent of the project is to be performed by the small business concern and at least 30 percent by the research institution. In both Phase I and Phase II, the research must be performed in the U.S. and its possessions. To be eligible for funding, a grant application must be approved for scientific merit and program relevance by a scientific review group and a national advisory council.

Beneficiary eligibility

Any nonprofit or for-profit organization, company, or institution engaged in biomedical research on cancer.

Uses of assistance

Grants and cooperative agreements may be made to eligible institutions for the support of cancer research projects. The grants and cooperative agreements may be used for personnel, consultant costs, equipment, supplies, travel, patient costs, animals, alterations and renovations, miscellaneous items, and indirect costs. Restrictions are imposed against the use of funds for entertainment, foreign travel (unless specifically authorized), office equipment, and other items not normally necessary for the effective prosecution of such research. SBIR Phase I grants (of approximately 6-months' duration) are to establish the technical merit and feasibility of a proposed research effort that may lead to a commercial product or process. Phase II grants are for the continuation of the research initiated in Phase I, and that are likely to result in commercial products or processes. Only Phase I awardees are eligible to receive Phase II support. STTR Phase I grants (normally of 1-year duration) are to determine the scientific, technical, and commercial merit and feasibility of the proposed cooperative effort that has potential for commercial application. Phase II funding is based on results of research initiated in Phase I and scientific and technical merit and commercial potential of Phase II application. The SBIR Fast-Track Initiative provides additional assistance to applicants by expediting the decision and award of SBIR Phase II funding for scientifically meritorious applications for projects that have a high potential for commercialization. Fast-Track is a parallel review option whereby Phase I and Phase II projects are reviewed concurrently with the aim of reducing or eliminating the funding gap between Phase I and Phase II.

Length and time phasing of assistance

Grants and Cooperative Agreements: Average 3 to 4 years, maximum of 5 years. Renewals may be awarded for additional periods of up to 5 years based on competitive peer review. Funding is provided through Monthly Demand Payment System or Letter of Credit. SBIR: Normally, Phase I awards are for 6 months; normally, Phase II awards are for 2 years. STTR: Normally, Phase I awards are for 1 year; normally, Phase II awards are for 2 years.

How to apply

Criteria for selecting proposals

The major elements in evaluating proposals include assessments of: (1) The scientific merit and general significance of the proposed study and its objectives; 2) the technical adequacy of the experimental design and approach; (3) the competency of the proposed investigator or group to successfully pursue the project; (4) the adequacy of the available and proposed facilities and resources; (5) the necessity of the budget components requested in relation to the proposed project; and (6) the relevance and importance to announced program objectives. The following criteria will be used in considering the scientific and technical merit of SBIR/STTR Phase I grant applications: (1) The soundness and technical merit of the proposed approach; (2) the qualifications of the proposed principal investigator, supporting staff, and consultants; (3) the technological innovation of the proposed research; (4) the potential of the proposed research for commercial application; (5) the appropriateness of the budget requested; (6) the adequacy and suitability of the facilities and research environment; and (7) where applicable, the adequacy of assurances detailing the proposed means for (a) safeguarding human or animal subjects, and/or (b) protecting against or minimizing any adverse effect on the environment. Phase II grant applications will be reviewed based upon the following criteria: (1) The degree to which the Phase I objectives were met and feasibility demonstrated; (2) the scientific and technical merit of the proposed approach for achieving the Phase II objectives; (3) the qualifications of the proposed principal investigator, supporting staff, and consultants; (4) the technological innovation, originality, or societal importance of the proposed research; (5) the potential of the proposed research for commercial application; (6) the reasonableness of the budget requested for the work proposed; (7) the adequacy and suitability of the facilities and research environment; and (8) where applicable, the adequacy of assurances detailing the proposed means for a) safeguarding human or animal subjects, and/or (b) protecting against or minimizing any adverse effect on the environment.

Award procedure

Grant applications are evaluated by scientific authorities for scientific and technical merit. Applications must also be reviewed by the National Cancer Advisory Board. All competitive applications compete for available funds on the basis of scientific and technical merit, program relevance, and program balance, consistent with NCI and NIH priorities and strategic plans. Initial award provides funds for the first budget period (usually 12 months) and Notice of Grant Award (Form PHS 1533-2) indicates support recommended for the remainder of the project period, allocation of Federal funds by budget categories, and special conditions, if any. All accepted SBIR/STTR applications are evaluated for scientific and technical merit by an appropriate scientific peer review panel and by a national advisory council or board. All applications receiving a priority score compete for available SBIR/STTR set-aside funds on the basis of scientific and technical merit and commercial potential of the proposed research, program relevance, and program balance among the areas of research.

Time to approval or disapproval

(Grants) Approximately 10 months. SBIR/STTR: About 7-1/2 months.

Renewals

Applications submitted for renewal must be reviewed and selected for funding on a competitive basis.

Appeals

A principal investigator (P.I.) may question the substantive or procedural aspects of the review of his/her application by communicating with the staff of the Institute. A description of the NIH Peer Review Appeal procedures is available online through the NIH home page at http://www.grants.nih.gov/grants/guide/notice-files/not97-232.html

Grant opportunities

Opportunity Status Posted Applications due
Investigator-Focused Award (Parent R35) PAR-28-037 Forecasted —
Advanced Development and Sustainment of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional) RFA-CA-28-003 Forecasted —
NCI Research Specialist (Clinician Scientist) Award (R50 Clinical Trial Not Allowed) PAR-27-089 Forecasted —
NCI Research Specialist Award for Core and Laboratory-based Scientists (R50 Clinical Trial Not Allowed) PAR-27-088 Forecasted —
Single Source: Coordinating Center (CC) for the Small Cell Lung Cancer (SCLC) Consortium (U24 Clinical Trial Not Allowed) PAR-27-009 Forecasted —
Canine Cancer Immunotherapy Network (K9CIN; U01 Clinical Trial Not Allowed) RFA-CA-26-010 Forecasted —
Early-Onset Cancers: Investigating Etiology, Mechanisms, and Early Detection Strategies (RP1 Clinical Trials Optional) PAR-28-014 Open
Pancreatic Cancer Detection Consortium: Research Units (U01 Clinical Trial Optional) PAR-28-056 Open
Pancreatic Cancer Detection Consortium: Management and Data Coordination Unit (U24 Clinical Trial Not Allowed) PAR-28-057 Open
NIH Research Program Projects (Parent P01 Clinical Trial Optional) PA-27-061 Open
NIH Collaborative International Research Project (Parent PF5 Clinical Trial Optional) PA-26-002 Open
Carcinogen Hazard Assessment Monographs Program (CHAMP) (R01 Clinical Trial Not Allowed) RFA-CA-28-013 Open
Implementation Science to Advance HIV Prevention, Treatment, and Care (R61/R33 Clinical Trial Optional) RFA-AI-27-018 Open
Centers for AIDS Research (CFAR) and Developmental Centers for AIDS Research (D-CFAR) (P30 Clinical Trial Not Allowed) PAR-28-090 Open
Palliative Care Research Across the Lifespan: Leveraging the Palliative Care Consortium (R01 Clinical Trial Optional) PAR-27-090 Open
Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional) PAR-27-072 Open
Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) PA-26-001 Open
Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional) RFA-CA-27-021 Closed
Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional) RFA-CA-27-020 Closed
Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional) RFA-CA-27-019 Open
NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional) PA-27-100 Open
NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional) PA-27-102 Open
NIH Small Business Innovation Research (SBIR) Phase IIB Strategic Breakthrough Award (Parent [R44] Clinical Trial Optional) PA-27-101 Open
Research Opportunities in Cancer Epidemiology Cohort Studies (U01 Clinical Trial Not Allowed) PAR-27-073 Open
Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15 Clinical Trial Required) PAR-27-078 Open
SBIR/STTR Commercialization Readiness Pilot (CRP) Program (Parent SB1 Clinical Trial Optional) PAR-27-098 Open
NCI Community Oncology Research Program (NCORP) Community Sites (UG1 Clinical Trial Not Allowed) RFA-CA-27-007 Closed
NCI Community Oncology Research Program (NCORP) Research Bases (UG1 Clinical Trial Required) RFA-CA-27-006 Closed
NCI Community Oncology Research Program (NCORP) Academic Community Sites (UG1 Clinical Trials Not Allowed) RFA-CA-27-008 Closed
Implementation and Evaluation of Databases to Examine AIDS RFA-AI-28-025 Forecasted —
Stephen I. Katz Early Stage Investigator Research Project Grant (R01 Clinical Trial Not Allowed) PAR-25-322 Open
Stephen I. Katz Early Stage Investigator Research Project Grant (R01 Basic Experimental Studies with Human Required) PAR-25-323 Closed
Limited Competition: Data Analysis and Sharing Center (DASC) for the MACS/WIHS Combined Cohort Study (MWCCS) (U01 Clinical Trials Not Allowed) RFA-HL-26-010 Closed
Limited Competition: Clinical Research Sites (CRS) for the MACS/WIHS Combined Cohort Study (MWCCS) (U01 Clinical Trial Not Allowed) RFA-HL-26-009 Closed
Leadership and Coordination Center (LACC) for the MACS/WIHS Combined Cohort Study (MWCCS) (U01 Clinical Trials Not Allowed) RFA-HL-26-011 Closed
Time-Sensitive Evaluation of Policies Affecting Health Behaviors and Chronic Disease Risk (R01-Clinical Trial Not Allowed) PAR-25-312 Closed
Multidisciplinary Studies of HIV/AIDS and Aging (R01 Clinical Trial Optional) PAR-25-354 Closed
Multidisciplinary Studies of HIV/AIDS and Aging (R21 Clinical Trial Optional) PAR-25-355 Closed
Unveiling Health and Healthcare Disparities in Non-Communicable and Chronic Diseases in Latin America: Setting the Stage for Better Health Outcomes Across the Hemisphere (R01 - Clinical Trials Not Allowed) PAR-25-377 Closed
Method to Extend Research in Time (MERIT) Award Extension Request (Type 4 eSubmission Clinical Trial Optional) PAR-25-324 Open
NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Not Allowed) PA-25-304 Open
NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed) PA-25-301 Open
NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Required) PA-25-306 Open
Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed) PAR-25-325 Open
Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Allowed) PAR-25-346 Open
Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional) PAR-25-321 Open
Informatics Tools for the Pangenome (U01 Clinical Trial Not Allowed) RFA-HG-25-007 Closed
Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15 Clinical Trial Not Allowed) PAR-25-298 Open
Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Clinical Trial Not Allowed) PAR-25-134 Open
The Role of Work in Health Disparities in the U.S. (R01 Clinical Trials Optional) PAR-25-292 Open
Show 40 more

Latest 50 listed here. See the rest on GovTribe.

Grant awards

Award Recipient Federal obligations Awarded
The non invasive post polypoectomy surveillance study (nippss) UG3CA309249 New York University $671,426
Understanding the oncogenic functions of ENL and AF9 for better leukemia therapies R01CA315895 Regents Of The University Of Michigan $622,070
Evolution of influencer-driven e-cigarette marketing on social media and its effect on e-cigarette perceptions and… R01CA300653 University Of Southern California $733,023
Critical role for HSF2 and HSP110 axis in regulation of pre-mrna splicing and radiation response R01CA300054 Augusta University Research Institute, Inc. $568,713
Dissemination and implementation of a network-based facilitation strategy to improve quality and comprehensiveness of… UG3CA315303 The University Of Iowa $668,189
Environment, genetics, and epigenetics of hepatocellular carcinoma risk in the US U01CA320916 The Trustees Of Columbia University In The City Of New York $717,924
A novel sunscreen formulation, broad spectrum UV protection for cancer prevention featuring photoreactivation to repair… R43CA314462 Framergy Inc. $400,000
Improving patient outcomes through a digital health delivered intervention to monitor and manage symptoms after… R41CA314618 MCC Health, Inc. $201,112
The human GUT microbiome and incident breast cancer: a prospective epidemiologic approach R37CA315609 Rutgers The State University Of New Jersey $723,569
Refining and expanding a culinary nutrition intervention for cancer patients and caregivers (recipe) R34CA304678 University Of Arizona $275,518

Latest 10 of 18,704 listed here. See the rest on GovTribe.

Top recipients by federal obligations

10 of 777 recipients listed here. See the rest on GovTribe.

Federal obligations by fiscal year

Fiscal year Federal obligations
FY2026 $727,696,547
FY2025 $1,421,006,015
FY2024 $1,551,610,254
FY2023 $1,718,579,026
FY2022 $1,598,270,484
FY2021 $1,380,383,037
FY2020 $703,931,059
FY2019 $694,327,663
FY2018 $667,213,298
FY2017 $666,983,648
FY2016 $652,922,074
FY2015 $668,460,292
FY2014 $667,802,193
FY2013 $695,421,190
FY2012 $760,605,505
FY2011 $748,116,897
FY2010 $732,679,525
FY2009 $689,856,886
FY2008 $345,364,514
FY2007 $445,240,481
FY2006 $676,336,073
FY2005 $716,675,134
FY2004 $714,213,000
FY2003 $633,767,021
FY2002 $587,606,973
FY2001 $256,453,079
Show all 26

Quick answers

What is Assistance Listing 93.393?

Assistance Listing 93.393 is Cancer Cause and Prevention Research, a federal grant program run by National Institutes of Health (Department of Health and Human Services).

What is the CFDA number for Cancer Cause and Prevention Research?

Its CFDA number is 93.393: Assistance Listing numbers were called CFDA numbers before 2018.

How much funding has Assistance Listing 93.393 awarded?

18,704 grant awards under 93.393 have obligated $20,360,631,536 in federal funds to 777 recipients.

Who receives the most funding from 93.393?

The recipients obligated the most under Cancer Cause and Prevention Research are The Univeristy Of Texas M.d. Anderson Cancer Center ($459,263,998), The Trustees Of Columbia University In The City Of New York ($356,555,437) and Dana-Farber Cancer Institute, Inc. ($347,629,130).

How much did 93.393 obligate in fiscal year 2025?

Grants under 93.393 obligated $1,421,006,015 in federal funds in fiscal year 2025.

Are there open grant opportunities under 93.393?

36 of the latest 50 opportunities under 93.393 are open or forecasted. The latest, Investigator-Focused Award (Parent R35), was posted on July 30, 2026.

On GovTribe

See this program's full record

  • Every grant award and opportunity under it
  • Funding by recipient, agency and assistance type
  • Alerts for new opportunities
  • Ask GovTribe AI about this program